Bioheart launches clinical trial for stem cell vision loss therapy
Florida regenerative therapies company Bioheart prepares to begin enrollment in a clinical study to evaluate stem cell treatment for patients with dry macular degeneration.
Regenerative therapies company Bioheart (OTC:BHRT) is about to embark on a clinical trial to evaluate its proprietary stem cell therapy in treatment of dry macular degeneration, a condition which results in loss of vision.
Bioheart will enroll up to 100 patients for treatment with its AdipoCell therapy, based on adipose derived stem cells. The trial won approval the Institutional Review Board of the International Cellular Medicine Society, Bioheart announced today.